


**ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass**

Rafael Barreto, Yukiko Kitase, Tsutomu Matsumoto, Fabrizio Pin, Kyra C. Colston,  
Katherine E. Couch, Thomas M. O'Connell, Marion E. Couch, Lynda F. Bonewald,  
Andrea Bonetto

## Supplementary Figure S1

**Administration of Folfiri for up to 5 weeks determines moderate muscle loss and muscle weakness in CD2F1 female mice.**



Muscle weights (**A**) and muscle strength (**B**) in female mice treated with either vehicle or Folfiri (n=5). Weights were normalized to the Initial Body Weight (IBW) and expressed as weight/100mg IBW. GSN: gastrocnemius. Data expressed as means  $\pm$  SD. Significance of the differences: \*p<0.05 vs. Vehicle.